Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Frontline Axi-Cel Elicits 74% CR Rate in High-Risk Large B-Cell Lymphoma
Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.
ZUMA-5: high ORR and CR for R/R iNHL with axi-cel
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, gives an update on the ongoing Phase II ZUMA-5 trial (NCT03105336) of axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR)-T cell therapy, for patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma and marginal zone lymphoma (MZL).
Interim results from ZUMA-12: Axi-cel as frontline treatment for high-risk LBCL
Patients with high-risk large B-cell lymphoma (LBCL) are mainly treated with rituximab-based chemoimmunotherapies that do not provide sufficient efficacy, as approximately 50% of these patients will not achieve long-term disease remission.
Interim data from phase II Zuma-5 study (axicabtagene ciloleucel in FL and MZL) ...
Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR T-cell therapy, leads to a high rate of strong and sustained responses in adults with relapsed or refractory (resistant) follicular lymphoma, known as FL, or marginal zone lymphoma, called MZL, who received at least two prior therapy lines, according to interim data from a Phase 2 trial.
Unanswered Questions Remain in DLBCL With Use of CAR T-Cell Therapies
In an interview with Targeted Oncology, Caron Jacobson, MD, discussed the data supporting use of CAR T-cell therapy as treatment of patients with diffuse large B-cell lymphoma and some of the remaining questions in this space that need to be addressed as these cellular therapies advanced forward in the field.